Skip to main content
. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933

Fig. 4.

Fig. 4

Title: Cardiovascular mortality or hospitalizations for HF was significantly lower in the SGLT2 inhibitor group. Legend: There was a significant 25% relative risk reduction in the composite endpoint of cardiovascular mortality or heart failure hospitalizations among patients with HF treated with SGLT2 inhibitors compared with placebo (OR 0•75; 95% CI 0•70–0•80).